Arbutus Biopharma Files 8-K
Ticker: ABUS · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Arbutus Biopharma filed an 8-K on April 4th. Standard corporate update.
AI Summary
Arbutus Biopharma Corporation filed an 8-K on April 4, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuticals Corp, is incorporated in British Columbia, Canada, and has its principal executive offices in Warminster, Pennsylvania.
Why It Matters
This filing provides an update on Arbutus Biopharma's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- April 4, 2024 (date) — Date of report
- Warminster, Pennsylvania (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of April 4, 2024.
When was Arbutus Biopharma Corporation's report filed?
Arbutus Biopharma Corporation's report was filed on April 4, 2024.
What was Arbutus Biopharma Corporation's former name?
Arbutus Biopharma Corporation was formerly known as TEKMIRA PHARMACEUTICALS Corp.
Where are Arbutus Biopharma Corporation's principal executive offices located?
Arbutus Biopharma Corporation's principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania.
In which jurisdiction is Arbutus Biopharma Corporation incorporated?
Arbutus Biopharma Corporation is incorporated in British Columbia, Canada.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-04 08:31:15
Filing Documents
- f8k_040424.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-24-001830.txt ( ) — 221KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_040424_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On April 4, 2024, Arbutus Biopharma Corporation (the "Company") issued a press release announcing the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by the Company and its licensee Genevant Sciences against Moderna, Inc. and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna's vaccine for COVID-19. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated April 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: April 4, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer